Table 1 Epidemiological and clinical features of the ChoCO-w population study
From: The ChoCO-W prospective observational global study: Does COVID-19 increase gangrenous cholecystitis?
Epidemiological and clinical features | Non-COVID 2412 | COVID N = 180 | p |
|---|---|---|---|
Age | 61.97 (17.3) | 63.93(15.8) | 0.21 |
Gender | 012 | ||
Male | 1268 (52.7%) | 84 (46.7%) | |
Female | 1140 (47.3%) | 96 (53.3%) | |
Setting of acquisition | 0.01 | ||
Community based | 2027 (89.5%) | 143(82.7%) | |
Hospital based | 239 (10.5%) | 30 (17.3%) | |
Immunodeficiency | 101 (4.2%) | 12 (6.7%) | 0.13 |
Malignancy | 167 (7%) | 13 (7.3%) | 0.88 |
Severe cardiovascular disease | 490 (20.4%) | 58 (32.2%) | p < 0.0001 |
Diabetes | p < 0.0001 | ||
No diabetes | 1856 (77%) | 126 (70%) | |
Prediabetes | 37 (1.5%) | 11 (6.1%) | |
History of diabetes | 123 (5.1%) | 16 (8.9%) | |
Diabetes without complications | 321 (13.3%) | 19 10.6%) | |
Diabetes with complication | 74 (3.1%) | 8 (4.4%) | |
Severe CKD | 91 (3.8%) | 8 (4.5%) | 0.55 |
Severe COPD | 155 (6.4%) | 22 (12.4%) | 0.005 |
ARDS | 24 (1%) | 27 (15.2%) | p < 0.0001 |
PIPAS score | 0 (0–7) | 1 (0–6) | p < 0.0001 |
WSES score | 1 (0–15) | 2 (0–16) | p < 0.0001 |
qSOFA score | 0 (0–5) | 0 (0–8) | p < 0.0001 |
Tokyo classification of severity of AC | 1.62 (0.66) | 1.87 (0.75) | p < 0.0001 |
Patients having complications | 282 (11.7%) | 57 (32.2%) | p < 0.0001 |
Clavien-Dindo complication score | 1 (1–4) | 2 (1–4) | p < 0.0001 |
Hospital stay (days) | 6.51 (5.6) | 13.21 (12.6) | p < 0.0001 |
Mortality | 40 (1.7%) | 24 (13.4%) | p < 0.0001 |